Filing Overview
Pyxis Oncology, Inc. filed a Form 8-K dated June 13, 2023, reporting the results of its 2023 Annual Meeting of Stockholders. The filing is not a periodic financial report and does not provide current-period financial statements or operating guidance.
Business Context and Reporting Period
The Annual Meeting was held virtually on June 13, 2023. As of the April 20, 2023 record date, 37,984,187 shares of common stock were outstanding and entitled to vote. A quorum was present with 27,514,417 shares represented in person or by proxy.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial performance metrics.
Material Changes Versus Prior Period
The filing does not report material financial or operating changes versus a prior comparable period.
Corporate Governance and Other Matters
- Rachel Humphrey, M.D. was elected as a Class I director, serving until the 2025 Annual Meeting and until a successor is elected and qualified.
- Freda Lewis-Hall, M.D. and Thomas Civik were elected as Class II directors, serving until the 2026 Annual Meeting and until their successors are elected and qualified.
- Ernst & Young LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
Vote Results
| Proposal or Nominee | For | Against or Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Rachel Humphrey, M.D. | 13,536,830 | 3,476,861 withheld | Not separately provided | 10,500,726 |
| Freda Lewis-Hall, M.D. | 13,597,586 | 3,416,105 withheld | Not separately provided | 10,500,726 |
| Thomas Civik | 13,452,770 | 3,560,921 withheld | Not separately provided | 10,500,726 |
| Auditor ratification | 27,404,246 | 80,518 | 29,653 | — |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, risk updates, contingencies, or unusual financial items. It confirms that Pyxis Oncology is an emerging growth company.
Key Facts for Investors to Verify
- Confirm the elected directors’ committee assignments, independence status, and tenure in subsequent filings.
- Review subsequent filings for any changes involving Ernst & Young LLP or the Company’s fiscal-year 2023 audit.
- Use the Company’s periodic reports, rather than this 8-K, to assess cash runway, liquidity, operating expenses, clinical-development spending, and financing needs.